By blocking the S100-PRR interaction, rCT-S100A8/9 can improve colitis while retaining the TLR4-dependent antibacterial defense mechanism, which may become a potential therapeutic target for CAC (Riddell et al., 1983; Francipane and Lagasse, 2013). This evidence concerns the gene TLR4 and colitis.